Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B 2022-01-17 18:12
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne 2022-01-13 17:30
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication 2022-01-11 08:30
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors 2022-01-10 08:30
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH 2022-01-04 08:30
Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus 2022-01-03 08:30
Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy 2021-12-03 12:05
First Subject Dosed in the U.S. Phase I Trial for ASC43F Only Half a Month after IND Approval by the U.S. FDA 2021-11-18 08:30
Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee 2021-11-16 08:35
Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis 2021-11-15 08:30
Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients 2021-11-10 08:30
Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study 2021-11-09 08:33
Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases 2021-11-08 08:30
Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH 2021-11-01 08:30
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases 2021-10-13 20:30
Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021 by American Association for the Study of Liver Diseases 2021-10-12 08:30
Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41 2021-09-08 08:30
Gannex Announces Clinical Trial Application of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis Accepted by China NMPA 2021-09-06 08:30
Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication 2021-08-25 08:30
Ascletis' Partner Sagimet Dosed First Patient in FASCINATE-2 Phase IIb Trial in NASH Patients with Moderate to Advanced Fibrosis 2021-08-16 21:30
1 3 4 5 6 7 9